{"id":"NCT00104052","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)","officialTitle":"Assessment of the Safety, Efficacy, Tolerability and Pharmacokinetics of PEG-Intron® Plus REBETOL® in Pediatric Patients With Chronic Hepatitis C","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-02","primaryCompletion":"2007-11","completion":"2007-11","firstPosted":"2005-02-23","resultsPosted":"2009-03-09","lastUpdate":"2017-04-04"},"enrollment":107,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"BIOLOGICAL","name":"peginterferon alfa-2b (PEG2b) (SCH 54031)","otherNames":["PEG-Intron (SCH 54031)"]},{"type":"DRUG","name":"ribavirin (SCH 18908)","otherNames":["REBETOL (SCH 18908)"]}],"arms":[{"label":"PEG-Intron alfa 2b (PEG2b) plus REBETOL (RBV)","type":"EXPERIMENTAL"}],"summary":"The primary objective is to assess the safety, efficacy and tolerability of the combination of PEG-Intron plus REBETOL in pediatric subjects with chronic hepatitis C. The secondary objective is to measure the multiple-dose pharmacokinetics of PEG-Intron and REBETOL in pediatric subjects with chronic hepatitis C.","primaryOutcome":{"measure":"Number of Participants With a Sustained Virologic Response (SVR) at 24 Weeks Post-treatment","timeFrame":"Up to 48-week treatment duration. Follow-up of 24 weeks.","effectByArm":[{"arm":"PEG-Intron Plus REBETOL","deltaMin":70,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":20},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["27111344","20189674"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":107},"commonTop":["PYREXIA","HEADACHE","VOMITING","NEUTROPENIA","FATIGUE"]}}